Optimal management of uterine leiomyosarcoma Journal Article
| Authors: | O'cearbhaill, R.; Hensley, M. L. |
| Article Title: | Optimal management of uterine leiomyosarcoma |
| Abstract: | Uterine leiomyosarcomas (LMSs) are rare tumors, comprising 1.3% of all uterine cancers. Primary therapy for localized disease entails complete surgical resection. The majority of patients recur within 2 years of primary therapy as these tumors tend to undergo early hematogenous spread. A randomized, controlled trial showed no improvement in the overall or disease-free survival with adjuvant radiotherapy, compared with observation, following resection of early-stage uterine LMS. A Phase II study of adjuvant chemotherapy following complete surgical resection of uterine LMS reported promising results. However, in the absence of Phase III randomized data demonstrating improved outcomes, the role of post-resection chemotherapy for early-stage disease remains experimental. For metastatic or unresectable LMS, systemic chemotherapy forms the mainstay of treatment. First-line treatment options include gemcitabine-docetaxel or doxorubicin with or without ifosfamide. Novel targeted therapies are under investigation in an attempt to devise more effective treatment strategies. © 2010 Expert Reviews Ltd. |
| Keywords: | cancer chemotherapy; cancer survival; treatment outcome; cancer surgery; overall survival; hydroxyurea; thalidomide; clinical trial; fatigue; neutropenia; paresthesia; review; cancer recurrence; sorafenib; bevacizumab; cisplatin; doxorubicin; sunitinib; advanced cancer; cancer combination chemotherapy; diarrhea; drug efficacy; drug potentiation; drug withdrawal; gastrointestinal hemorrhage; side effect; skin toxicity; clinical trials as topic; gemcitabine; paclitaxel; adjuvant therapy; cancer radiotherapy; disease free survival; combined modality therapy; chemotherapy; temozolomide; topotecan; cancer staging; drug megadose; neurotoxicity; recurrent cancer; salpingooophorectomy; anorexia; cancer palliative therapy; lymphadenectomy; dacarbazine; unindexed drug; metastasis; drug eruption; liver toxicity; lung toxicity; multiple cycle treatment; anemia; bone marrow suppression; etoposide; mucosa inflammation; nausea; thrombocytopenia; vomiting; myalgia; radiotherapy; recurrence; cyclophosphamide; vincristine; continuous infusion; radiation injury; cancer mortality; ifosfamide; docetaxel; abdominal pain; asthenia; cancer hormone therapy; drug hypersensitivity; dyspnea; febrile neutropenia; sarcoma; gastrointestinal toxicity; pneumothorax; mitoxantrone; soft tissue sarcoma; brachytherapy; surgical resection; cancer epidemiology; intestine perforation; external beam radiotherapy; mesna; trabectedin; leiomyosarcoma; navelbine; mitomycin; anthracycline; cryoablation; radiofrequency ablation; hand foot syndrome; uterine neoplasms; granulocyte colony stimulating factor; enteropathy; abdominal hysterectomy; uterine leiomyosarcoma; uterus leiomyosarcoma; uterus sarcoma; hormone therapy; drug induced disease; liposarcoma; bone marrow toxicity; bladder disease; medroxyprogesterone acetate; myomectomy; carcinosarcoma; staging system; vagina bleeding; foot edema; hypertransaminasemia; anti-angiogenics; metastectomy; thermal ablation; aminothiadiazole; amonafide; diaziquone; trimetrexate; heart ejection fraction |
| Journal Title: | Expert Review of Anticancer Therapy |
| Volume: | 10 |
| Issue: | 2 |
| ISSN: | 1473-7140 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2010-02-01 |
| Start Page: | 153 |
| End Page: | 169 |
| Language: | English |
| DOI: | 10.1586/era.09.187 |
| PUBMED: | 20131992 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 2" - "Export Date: 20 April 2011" - "CODEN: ERATB" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
271O'Cearbhaill -
289Hensley
Related MSK Work